Vericiguat tablet

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Khawaja Danish Ali, National Institute of Cardiovascular Diseases, Pakistan

Conditions

Decompensated Heart FailureHeart FailureHeart Failure With Reduced Ejection Fraction (HFrEF)Left Ventricular Systolic Dysfunction

Phase 1

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

RecruitingNCT07444398

Khawaja Danish AliDecompensated Heart Failure

Start: 2026-01-01End: 2026-03-31Target: 130Updated: 2026-03-02

Phase 2

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

RecruitingNCT05714085

Merck Sharp & Dohme LLCHeart Failure, Left Ventricular Systolic Dysfunction

Start: 2023-05-31End: 2032-04-15Target: 342Updated: 2026-07-13

Phase 4

Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients

Not yet recruitingNCT07697833

National Institute of Cardiovascular Diseases, PakistanHeart Failure With Reduced Ejection Fraction (HFrEF)

Start: 2026-07-15End: 2027-07-31Target: 500Updated: 2026-07-13

Related Papers

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.

2024-06-256 citations